XXII Achieves “Holy Grail” of Cannabis Plant Science
22nd Century Group (XXII) just announced a breakthrough in its hemp/cannabis plant research leading to the successful transformation of the hemp/cannabis plant genome using a proprietary plant transformation and regeneration technology and clear protein expression by the introduced genes. This is huge news and could totally transform the cannabis industry as we know it.
Keep reading to see Cannin’s Technical Assessment to see if this XXII stock is a strong buy.
22nd Century has previously demonstrated its ability to generate new, tailored hemp/cannabis lines through broad-based techniques such as molecular breeding and mutagenesis, which necessitate the creation of hundreds or thousands of plants that are then genetically sequenced to identify those with the desired genetic traits. The plant transformation breakthrough unlocked by 22nd Century and KeyGene enables the desired DNA sequences to be inserted directly into or created from a plant’s existing genetic material, creating a more expedient and focused methodology to achieve the desired outcome.
“I cannot emphasize enough what an enormous achievement it is for our company to have cracked the code to show proof of genome transformation in the hemp/cannabis plant. This is the holy grail in plant science and places us in a commanding leadership position in the race to secure patents and other valuable intellectual property in the emerging hemp/cannabis genetics field,” said James A. Mish, chief executive officer of 22nd Century Group. “These newest plant transformation discoveries unlock additional revenue opportunities for the Company and accelerate our efforts to create new hemp/cannabis plant lines with much higher commercial value at accelerated rates, lower cost and lower risk to our customers.”
In addition to its transformation capability, 22nd Century Group has exclusive access to a battery of gene-editing capabilities, based on meganuclease technology, directed to seven of the key enzymes for the biosynthesis of cannabinoids, plus four patent families that cover vital enzymes. Unlike other more widely available gene-editing technologies like CRISPR-CAS-9, this technology is allowed for use in cannabis. These capabilities and IP provide 22nd Century a huge competitive advantage in the field.
What are XXII Technicals Telling Us? Is XXII a Strong Buy?
is xxii a strong buy
- XXII shares holding the $20 support area.
- News of low nicotine content cigarettes had buyers in big volume a few week ago
- Buyers have given up those gains and stock seem to have found support at $2 a share
- Long term projection of charts bullish as long as stock finds support around $2 a share and rises above $4 a share
- Market cap $350 million at $2.25 a share
- Currently, back in the middle of trading range of last few years
- XXII needs to be above $4 for long term bullish to be in control. Add XXII to your watchlist and watch for the long term bullish trend
Related: 22nd Century: Is this Cannabis Stock a Buy and Hold?
XXII Achieves Holy Grail of Cannabis Plant Science
About Cannin: Your Cannabis Stocks Resource
78% of Cannin’s fundamentals prove true within 30 days or less on 100+ recommendations over the past 2 years.
Cannin is your #1 trusted resource for cannabis stocks. Our global team of experts evaluates all emerging cannabis stock investing opportunities. In fact, we aggregate hundreds of hours of financial research and provide tips on the best cannabis stocks for 2021.
Use Cannin as your resource for:
Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.
Are you looking to buy stock in hemp companies or marijuana companies for 2021? If so, are you interested in new penny hemp stock companies? Or, looking for the best Canadian cannabis stocks to invest in? Maybe, you’re looking to leverage the power of algorithmic stock trading to beat the cannabis market? We can help.
Are you interested in cannabis stocks like Curaleaf, Trulieve, Aurora Cannabis, Charlotte’s Web, Canopy Growth, or Hemp Inc.?
Predict price movements of cannabis stocks several hours in advance with our proprietary algorithmic stock trading software.
- +34% Gains in 2022
- +56% Gains in 2021
- +30% Gains in 2020
- +49.8% Gains in 2019
- Backtested since 2012
In fact, we’re so confident you’ll love our algotrading cannabis stock signals, we’re willing to give you a one week risk-free trial to see it for yourself.
Profit from the best cannabis stocks – we’ll show you how at cannin.com.
